HIV-1 Replication in Langerhans and Interstitial Dendritic Cells Is Inhibited by Neutralizing and Fc-Mediated Inhibitory Antibodies
- 15 January 2011
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (2), 1077-1085
- https://doi.org/10.1128/jvi.01619-10
Abstract
Langerhans cells (LCs) and interstitial dendritic cells (IDCs) may be among the first human immunodeficiency virus type 1 (HIV-1) targets after sexual transmission. We generated cells of these types by differentiation of purified CD34 + cord blood cells. After in vitro infection with R5-tropic strains, we obtained similar percentages of infected cells for both dendritic cell (DC) subsets. Moreover, LC infection was not increased by blockage of langerin by antilangerin. These results indicate that, under our experimental conditions, there was no evidence of any preference of HIV replication in LCs versus IDCs. The inhibitory activity of HIV-1-specific IgAs and IgGs against HIV-1 replication in LCs and IDCs was analyzed. We found that neutralizing antibodies inhibit HIV-1 infection of both DC subsets. Interestingly, HIV-1 was inhibited more efficiently by the IgGs than the corresponding IgA, due to an Fcγ receptor-dependent mechanism. Moreover, nonneutralizing inhibitory IgGs were able to inhibit infection of both LCs and IDCs. These results underline the importance of HIV-1 inhibition by the binding of the Fc part of IgGs to Fcγ receptors and suggest that the induction of neutralizing and nonneutralizing inhibitory IgGs in addition to neutralizing IgAs at mucosal sites may contribute to protection against sexual transmission of HIV-1.This publication has 40 references indexed in Scilit:
- Macaques Vaccinated with Simian Immunodeficiency Virus SIVmac239Δnef Delay Acquisition and Control Replication after Repeated Low-Dose Heterologous SIV ChallengeJournal of Virology, 2010
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Introduction: Back to basics: mucosal immunity and novel HIV vaccine conceptsJournal of Internal Medicine, 2008
- Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccinationVirology, 2008
- Human Langerhans’ cells and dermal‐type dendritic cells generated from CD34 stem cells express different toll‐like receptors and secrete different cytokines in response to toll‐like receptor ligandsImmunology, 2008
- FcγR: The key to optimize therapeutic antibodies?Critical Reviews in Oncology/Hematology, 2007
- Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1Immunity, 2007
- Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic CellsJournal of Virology, 2006
- Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T CellsJournal of Virology, 2002